跳至主要内容
临床试验/NCT05023837
NCT05023837已完成不适用

Evaluation of the Efficacy of Immunotherapy in Uncommon Pathological Types of Lung Cancer

Hunan Province Tumor Hospital1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2018年3月2日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
40
试验地点
1
主要终点
PFS

研究概览

简要总结

This study was designed to explore the efficacy and safety of immune checkpoint inhibitor for advanced uncommon pathological types of lung cancer whether or not it is accompanied by a driver mutationin the real world. Through retrospective collection of clinical data of patients with uncommon pathological types of lung cancer.The patients who are treated with immunosuppressive agents are screened out, and they are divided into immune combination therapy or immune monotherapy, and further evaluate whether there is a difference in efficacy between the two.

详细描述

This is a research project involving patients in Medical Oncology Department of Affiliated Cancer Hospital of Xiangya School of Medicine Central South University. Retrospective study of 40 patients with advanced uncommon pathological types of lung cancer and observe the efficacy and safety of immune checkpoint inhibitor regimen in the real world. The patients who are treated with immunosuppressive agents are screened out, and they are divided into immune combination therapy or immune monotherapy, and further evaluate whether there is a difference in efficacy between the two. Statistical analysis is used to compare the differences between the two treatments, so that patients can better choose treatment strategies.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 18,Advanced uncommon pathological types of lung cancer by histopathology whether or not it is accompanied by a driver mutation Treatment Plan is pembrolizumab 200mg iv q21d

排除标准

  • Patients received antitumor treatment before Patients with contraindication of chemotherapy Pregnant or breast feeding women

结局指标

主要结局

PFS

时间窗: may 2019- may 2021

progression survival time

次要结局

  • OS(may 2019- may 2021)

研究者

发起方
Hunan Province Tumor Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

Yongchang Zhang

Professor

Hunan Province Tumor Hospital

研究点 (1)

Loading locations...

相似试验